# EDGAR Filing Document

**Accession Number:** 0001952164
**File Stem:** 0001829126-23-001528
**Filing Date:** 2023-2
**Character Count:** 22111
**Document Hash:** 6f738a69fb982b855aaf7d9de613a369
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-23-001528.hdr.sgml**: 20231011

**ACCESSION NUMBER**: 0001829126-23-001528

**CONFORMED SUBMISSION TYPE**: SC 13D/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Organicell Regenerative Medicine, Inc.
- **CENTRAL INDEX KEY:** 0001557376
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 474180540
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87575
- **FILM NUMBER:** 23630323

**BUSINESS ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314
- **BUSINESS PHONE:** 888-963-7881

**MAIL ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biotech Products Services & Research, Inc.
- **DATE OF NAME CHANGE:** 20150917

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BESPOKE TRICYCLES INC
- **DATE OF NAME CHANGE:** 20120831
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Skycrest Holdings, LLC
- **CENTRAL INDEX KEY:** 0001952164
- **IRS NUMBER:** 980594973

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 1930 HARRISON STREET
- **STREET 2:** SUITE 204
- **CITY:** HOLLYWOOD
- **STATE:** FL
- **ZIP:** 33020
- **BUSINESS PHONE:** 954-701-4123

**MAIL ADDRESS:**
- **STREET 1:** 1930 HARRISON STREET
- **STREET 2:** SUITE 204
- **CITY:** HOLLYWOOD
- **STATE:** FL
- **ZIP:** 33020

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 1)\***

**Organicell Regenerative Medicine, Inc.**

(Name of Issuer)

common stock $0.001 par value and Series C preferred stock $0.001 par value

(Title of Class of Securities)

**09074L105**

(CUSIP Number)

Ian Bothwell, CFO,

4045 Sheridan Ave., Suite 239,

Miami Beach, FL 33140

Name, Address and Telephone Number of Person Authorized to

Receive Notices and Communications)

August 16, 2022

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**SCHEDULE 13D**

CUSIP No. 09074L105

---

| | | | |
|:---|:---|:---|:---|
| 1. | Names of Reporting Persons.<br>Skycrest Holdings, LLC | Names of Reporting Persons.<br>Skycrest Holdings, LLC | Names of Reporting Persons.<br>Skycrest Holdings, LLC |
| 2. | Check the Appropriate Box if a Member of a Group<br> (a) ☐<br> (b) ☒ | Check the Appropriate Box if a Member of a Group<br> (a) ☐<br> (b) ☒ | Check the Appropriate Box if a Member of a Group<br> (a) ☐<br> (b) ☒ |
| 3. | SEC Use Only | SEC Use Only | SEC Use Only |
| 4. | Source of Funds<br>WC | Source of Funds<br>WC | Source of Funds<br>WC |
| 5. | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)<br> Not applicable<br> ☐ | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)<br> Not applicable<br> ☐ | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)<br> Not applicable<br> ☐ |
| 6. | Citizenship or Place of Organization<br>Nevada | Citizenship or Place of Organization<br>Nevada | Citizenship or Place of Organization<br>Nevada |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each Reporting<br> Person With: | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each Reporting<br> Person With: | 7. | Sole Voting Power<br> 31.5% <sup>(1)</sup> |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each Reporting<br> Person With: | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each Reporting<br> Person With: |  | Consists of the voting power held from ownership of common stock of the Issuer (including common stock issuable upon exercise of warrants) and the 25.5% voting power due to ownership of Series C Non-Convertible Preferred Stock of the Issuer. Based on 1,476,126,390 shares of common stock of the Issuer outstanding as of September 14, 2022 and the 51% aggregate voting power held by holders of Series C Non-Convertible Preferred Stock of the Issuer |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each Reporting<br> Person With: | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each Reporting<br> Person With: | 8. | Shared Voting Power<br>0 shared voting power |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each Reporting<br> Person With: | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each Reporting<br> Person With: | 9. | Sole Dispositive Power<br>200,000,000 shares (including 50,000,000 shares of common stock of the Issuer and 150,000,000 shares of common stock of the Issuer issuable upon exercise of warrants. |
| Number of<br> Shares<br> Beneficially<br> Owned by<br> Each Reporting<br> Person With: | Number of<br> Shares<br> Beneficially<br> Owned by<br> Each Reporting<br> Person With: | 10. | Shared Dispositive Power<br>0 shared dispositive power |
| 11. | Aggregate Amount Beneficially Owned by Each Reporting Person<br> 31.5% <sup>(2)</sup> | Aggregate Amount Beneficially Owned by Each Reporting Person<br> 31.5% <sup>(2)</sup> | Aggregate Amount Beneficially Owned by Each Reporting Person<br> 31.5% <sup>(2)</sup> |
|  | Consists of the voting power held from ownership of common stock of the Issuer (including common stock issuable upon exercise of warrants) and the 25.5% voting power due to ownership of Series C Non-Convertible Preferred Stock of the Issuer. Based on 1,476,126,390 shares of common stock of the Issuer outstanding as of September 14, 2022 and the 51% aggregate voting power held by holders of Series C Non-Convertible Preferred Stock of the Issuer | Consists of the voting power held from ownership of common stock of the Issuer (including common stock issuable upon exercise of warrants) and the 25.5% voting power due to ownership of Series C Non-Convertible Preferred Stock of the Issuer. Based on 1,476,126,390 shares of common stock of the Issuer outstanding as of September 14, 2022 and the 51% aggregate voting power held by holders of Series C Non-Convertible Preferred Stock of the Issuer | Consists of the voting power held from ownership of common stock of the Issuer (including common stock issuable upon exercise of warrants) and the 25.5% voting power due to ownership of Series C Non-Convertible Preferred Stock of the Issuer. Based on 1,476,126,390 shares of common stock of the Issuer outstanding as of September 14, 2022 and the 51% aggregate voting power held by holders of Series C Non-Convertible Preferred Stock of the Issuer |
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares<br> Not applicable<br> ☐ | Check if the Aggregate Amount in Row (11) Excludes Certain Shares<br> Not applicable<br> ☐ | Check if the Aggregate Amount in Row (11) Excludes Certain Shares<br> Not applicable<br> ☐ |
| 13. | Percent of Class Represented by Amount in Row (11)<br> 12.3% <br> Based upon ownership of 50,000,000 shares of common stock of the Issuer and 150,000,000 shares of common stock of the Issuer issuable upon exercise of warrants. | Percent of Class Represented by Amount in Row (11)<br> 12.3% <br> Based upon ownership of 50,000,000 shares of common stock of the Issuer and 150,000,000 shares of common stock of the Issuer issuable upon exercise of warrants. | Percent of Class Represented by Amount in Row (11)<br> 12.3% <br> Based upon ownership of 50,000,000 shares of common stock of the Issuer and 150,000,000 shares of common stock of the Issuer issuable upon exercise of warrants. |
| 14. | Type of Reporting Person<br>OO | Type of Reporting Person<br>OO | Type of Reporting Person<br>OO |

---

**ITEM 1. SECURITY AND ISSUER**

State the title of the class of equity securities to which this statement relates and the name and address of the principal executive offices of the issuer of such securities.

**ITEM 2. IDENTITY AND BACKGROUND**

If the person filing this statement or any person enumerated in Instruction C of this statement is a corporation, general partnership, limited partnership, syndicate or other group of persons, state its name, the state or other place of its organization, its principal business, the address of its principal office and the information required by (d) and (e) of this Item. If the person filing this statement or any person enumerated in Instruction C is a natural person, provide the information specified in (a) through (f) of this Item with respect to such person(s).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Name;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Residence or business address;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Whether or not, during the last five years, such person has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) and, if so, give the dates, nature of conviction, name and location of court, and penalty imposed, or other disposition of the case;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Whether or not, during the last five years, such person was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws; and, if so, identify and describe such proceedings and summarize the terms of such judgment, decree or final order; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Citizenship.

**ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION**

State the source and the amount of funds or other consideration used or to be used in making the purchases, and if any part of the purchase price is or will be represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the securities, a description of the transaction and the names of the parties thereto. Where material, such information should also be provided with respect to prior acquisitions not previously reported pursuant to this regulation. If the source of all or any part of the funds is a loan made in the ordinary course of business by a bank, as defined in Section 3(a)(6) of the Act, the name of the bank shall not be made available to the public if the person at the time of filing the statement so requests in writing and files such request, naming such bank, with the Secretary of the Commission. If the securities were acquired other than by purchase, describe the method of acquisition.

**ITEM 4. PURPOSE OF TRANSACTION**

State the purpose or purposes of the acquisition of securities of the issuer. Describe any plans or proposals which the reporting persons may have which relate to or would result in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) A sale or transfer of a material amount of assets of the issuer or any of its subsidiaries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Any material change in the present capitalization or dividend policy of the issuer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Any other material change in the issuer's business or corporate structure including but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Changes in the issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) A class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) Any action similar to any of those enumerated above.

**ITEM 5. INTEREST IN SECURITIES OF THE ISSUER**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) State the aggregate number and percentage of the class of securities identified pursuant to Item 1 (which may be based on the number of securities outstanding as contained in the most recently available filing with the Commission by the issuer unless the filing person has reason to believe such information is not current) beneficially owned (identifying those shares which there is a right to acquire) by each person named in Item 2. The above mentioned information should also be furnished with respect to persons who, together with any of the persons named in Item 2, comprise a group within the meaning of Section 13(d)(3) of the Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) For each person named in response to paragraph (a), indicate the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition. Provide the applicable information required by Item 2 with respect to each person with whom the power to vote or to direct the vote or to dispose or direct the disposition is shared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Describe any transactions in the class of securities reported on that were effected during the past sixty days or since the most recent filing of Schedule 13D (ss.240.13d-191), whichever is less, by the persons named in response to paragraph (a).

Instruction. The description of a transaction required by Item 5(c) shall include, but not necessarily be limited to: (1) the identity of the person covered by Item 5(c) who effected the transaction; (2) the date of the transaction; (3) the amount of securities involved; (4) the price per share or unit; and (5) where and how the transaction was effected.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of an employee benefit plan, pension fund or endowment fund is not required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) If applicable, state the date on which the reporting person ceased to be the beneficial owner of more than five percent of the class of securities.

Instruction. For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1) and the note thereto.

**ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER**

Describe any contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, naming the persons with whom such contracts, arrangements, understandings or relationships have been entered into. Include such information for any of the securities that are pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities except that disclosure of standard default and similar provisions contained in loan agreements need not be included.

**ITEM 7. MATERIAL TO BE FILED AS EXHIBITS**

The following shall be filed as exhibits: copies of written agreements relating to the filing of joint acquisition statements as required by ss.240.13d-1(k) and copies of all written agreements, contracts, arrangements, understandings, plans or proposals relating to: (1) the borrowing of funds to finance the acquisition as disclosed in Item 3; (2) the acquisition of issuer control, liquidation, sale of assets, merger, or change in business or corporate structure or any other matter as disclosed in Item 4; and (3) the transfer or voting of the securities, finder's fees, joint ventures, options, puts, calls, guarantees of loans, guarantees against loss or of profit, or the giving or withholding of any proxy as disclosed in Item 6.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

<u>February 13, 2023</u>

Date

<u>/s/ Louis Birdman</u>

Signature

<u>Louis Birdman, Manager</u>

Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

## Corresp

![](corresp_001.jpg)

February 13, 2023

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Mergers & Acquisitions

Michael Killoy

Nicholas Panos

Re: Organicell Regenerative Medicine, Inc.

Schedule 13D filed by Skycrest Holdings, LLC

Filed December 30, 2022

File No. 005-87575

Dear Mssrs. Killoy and Panos:

Please accept the following in response to your letter of January 20, 2023 addressed to Ian Bothwell. Your correspondence has been forwarded to the undersigned for response. In your letter, you request an explanation for the delay in delay in filing of the Schedule 13D of Skycrest Holdings, LLC. In response thereto, the delay was completely inadvertent as there was a misunderstanding among several individuals as to the responsibility for submitting the appropriate filing on behalf of Skycrest Holdings, LLC. In addition, there was some difficulty in converting the schedule to html and obtaining the appropriate Edgar codes for Skycrest's filing.

In the interim, please be advised that Skycrest Holdings, LLC has not made any additional investments in the Issuer, Organicell Regenerative Medicine, Inc.

In response to the qualitative disclosure narrative for the items required, an Amendment is being filed simultaneously with this response letter.

I trust that this correspondence sufficiently addresses the concerns raised in your January 20 correspondence. Should that not be the case, please contact the undersigned.

Sincerely,

/s/ Edward T. Anderson